Abstract
Abstract Osteoarthritis is a highly prevalent joint disorder affecting over 30 million adults in the United States. This debilitating disorder is associated with pain and decreased physical function. Though total joint arthroplasty is generally successful, this procedure has associated risk and many patients still have residual pain. Non-operative treatments have been investigated to provide patients with durable pain relief while not exposing them to increased risk. Orthobiologics, such as platelet-rich plasma, bone marrow aspirate concentrate, and amniotic products, contain cytokines and/or mesenchymal progenitor cells that have been demonstrated to modulate the pathogenesis of osteoarthritis in animal and basic science models and may provide clinical improvement in the clinical setting. This chapter will cover recent clinical trials involving orthobiologic injections in patients with hip or knee osteoarthritis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
